Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,377 INR | +6.44% | +8.01% | +14.04% |
05-03 | INDIA STOCKS-India's Nifty 50 slips from record high as IT stocks weigh | RE |
05-02 | Ajanta Pharma's Consolidated Profit Nearly Doubles in Fiscal Q4 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With an expected P/E ratio at 37.56 and 32.31 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.04% | 3.37B | - | ||
+19.98% | 43.67B | B- | ||
+20.67% | 22.51B | B+ | ||
+14.56% | 14.6B | - | ||
+14.32% | 13.74B | B+ | ||
+44.72% | 11.91B | B | ||
-8.37% | 7.04B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+11.90% | 5.42B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AJANTPHARM Stock
- 532331 Stock
- Ratings Ajanta Pharma Limited